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Key statement:  Any potential increase in opiate use that might result from availability of 
take home naloxone is more than outweighed by its benefits in preventing overdose deaths. 
 
What is the Concern? 
Administration of the opioid antagonist naloxone unquestionably saves lives and reduces organ 
damage by reversing respiratory depression from heroin/opioid overdose. The antidote is 
commonly available in emergency rooms and ambulances and has become standard equipment 
for many police officers and fire fighters. Broader public health efforts include take-home 
naloxone (THN) (1), i.e. pre-provision of an emergency naloxone supply to community 
members likely to experience or witness overdose, including people who use opioids (PWUO) 
and their close contacts. Multiple systematic reviews and studies have concluded that THN 
programs reduce opioid overdose mortality (2–7).  
 
Nonetheless, lack of published data from randomized controlled trials makes THN prone to 
scepticism. Critics argue that overdose mortality is rising while THN expands (e.g. in the U.S. 
and Scotland (8,9)), because of ‘Moral Hazard’, i.e. by making opioids safer THN leads users 
to taking greater risks, such as consuming fentanyl (10). Doleac and Mukherjee claim that the 
evidence for THN is uncertain, citing a 14% mortality increase associated with broadened 
naloxone access (11). However, others have since highlighted methodological flaws (12) in 
Doleac and Mukherjee’s analysis and have offered plausible alternative explanations for the 
rise in deaths, including changes in drug supply (e.g. fentanyl) (13).  
 
This editorial asks whether there is any basis for the concern that THN availability increases 
opioid use and how we can frame this discussion to provide a reasoned understanding. 
 
The Need for a Balanced View  
As scientists, it is our duty to raise questions that allow for balanced examination of the 
available evidence: what unintended consequences of THN availability exist, and with what 
frequency and real-world implications do these occur? Analogies from other aspects of health 
and behaviour are manifold. For example, might people drive faster because their cars have 
seatbelts and/or an anti-lock braking system (ABS)? Might Epi-Pens encourage people with 
food allergies to make riskier (i.e. potentially allergenic) food choices?  
 
A framework and a priori analytical approach would support a balanced examination. For an 
opioid overdose death to occur, at least two preceding steps exist – firstly, a pattern of drug use 
to produce the overdose, and secondly the absence or insufficiency of emergency resuscitative 
measures. Analyses of benefit from THN have focused on the latter (emergency resuscitation), 
but the former (overdose frequency and severity) also needs consideration.  
 
A macro-level perspective is also required, with crucial assessment of the extent of behavior 
change and effect size at population level. The net effect of any public safety measure is a 
function of two variables, namely risk compensation and intervention effect. To illustrate, seat 
belts may encourage people to drive faster, but their effect in saving lives during accidents is 
so large that they are a net benefit for public health (14). 
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Measuring Unintended Consequences of THN 
To date, only self-report data have been published, finding no overall increase in heroin use 
following THN receipt (15). Although these data are encouraging, a closer look reveals a more 
varied picture: while two-thirds (65%) of PWUO (n=325) reported unchanged or less frequent 
use, approximately one third (35%) increased use. But as with any self-report data, we need to 
assume potential limitations and biases (e.g. participants may have viewed it as socially 
desirable to report no increase in use). Moreover, for those already using heroin daily, the 
outcome measure (number of days using in past 30 days) was insensitive to increases in dose 
or frequency (i.e. greater than daily).  
 
Objective data sources may offer more reliable observations. Can we incorporate smart devices 
to detect individual patterns of opioid use and changes in frequency or severity? Although such 
technological innovations are still being developed, existing databases may offer proxy 
outcomes. For example, ambulance call-outs (16) for overdoses within a predetermined 
timeframe post-THN receipt may indicate increased opioid use. However, ambulance calls are 
an important and expected aspect of THN distribution, administration, and aftercare. There is 
thus difficulty in distinguishing between intended and unintended consequences of THN.  
 
A separate question concerns whether increased opioid use is truly an unintended outcome. 
Since dead people do not use drugs, and THN can prevent PWUO from dying, it has potential 
to increase population-wide opioid use by design. By analogy, public-access defibrillators 
increase the prevalence of heart attacks because some of those who otherwise (i.e. without 
defibrillation) would have died may go on to have future heart attacks. 
 
Should policymakers make THN provision contingent upon its potential effects on opioid use? 
For the sake of argument, if broadened THN distribution increased opioid use in 10% of 
recipients, but the overall effectiveness of resuscitation across the whole population improved 
by 20%, then policymakers could decide that the overall situation is still one of major gain. If, 
on the other hand, 50% of THN recipients increased their use, while successful resuscitation 
rates only improved by 5%, then this is of concern. 
 
Crucially, THN is one response of many in reducing overdose deaths, albeit an essential one. 
A recent study that modelled policy responses to address the U.S. opioid crisis noted that, 
among 11 interventions (including medication-assisted and psychosocial treatments, needle 
exchange services), naloxone availability would have the greatest effect on opioid-related 
deaths (with a 4% reduction), if considered alone (17). However, the authors concluded that a 
concerted effort rather than a single policy is required to substantially reduce deaths.  
 
Although unintended consequences of THN provision cannot be ruled out (and future policy 
and practice should address these to the extent possible), greater harm could emerge from 
“reputational toxicity” (18) of the intervention. Myths around unintended consequences (based 
on anecdotal or unreliable evidence) can give THN a bad reputation, and such unfounded 
perception of risk could discourage providers from prescribing naloxone, which would reduce 
the net benefit of THN.  
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In summary, whilst there may be some individuals and circumstances in which THN 
availability could have unintended negative consequences, the cumulative effect remains a 
major benefit. Nevertheless, this should be quantified and studied without it being viewed as a 
betrayal of commitment to pursuing the benefits of THN or harm reduction.  
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